SPRO
Spero Therapeutics, Inc.
$2.85
+5.56%
$165.0M
No data for this timeframe.
Vol
Market Cap$165.0M
Cap SizeMicro Cap
Inst. Holders23 funds
Inst. Value$14.1M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 7S
Insider Net $-$336.7K
Reddit Sentiment56° Neutral
SEC Reports2
Press Releases2
Recent Activity
Jun 18, 2026
fda_pdufa
PDUFA: SPRO — tebipenem HBr in complicated urinary tract infections (cUTI), including pyelonephritis — 2026-06-18
FDA target action date 2026-06-18 for SPRO (Spero Therapeutics, Inc.). Drug: tebipenem HBr. Indicati
May 13, 2026
SEC
Spero Therapeutics reported Q1 2026 results with revenue plunging 95% to $0.3M as the Phase 3 trial ended, but net loss
8-K — Impact 5/10
May 4, 2026
Insider
Rajavelu Esther sold 25,240 shares
See Remarks @ $2.51 ($63.4K)
Apr 27, 2026
SEC
Spero Therapeutics filed additional proxy materials for its 2026 Annual Meeting, scheduled for June 23, 2026. Proposals
DEFA14A — Impact 3/10
Mar 26, 2026
Press
Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177
Impact 8/10
Mar 18, 2026
Press
Spero Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, after market
Impact 4/10
Feb 6, 2026
Insider
Keutzer Timothy sold 18,652 shares
Chief Operating Officer @ $2.36 ($44.0K)
Feb 6, 2026
Insider
Rajavelu Esther sold 37,101 shares
See Remarks @ $2.36 ($87.6K)
Price Targets
Historical data — last covering-analyst action Jan 2025. No current recommendation available.
$4.00 (Jan 2025)
Current $2.85
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 30, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 20, 2024 | Evercore ISI Group | DOWNGRADE | Outperform → In-Line |
| Dec 2, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 18, 2024 | TD Cowen | DOWNGRADE | Buy → Hold |
| Nov 15, 2024 | Cantor Fitzgerald | REITERATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $0.67 | $0.67 — $0.67 | 347% YoY | 1 |
| Next FY | $0.76 | $0.76 — $0.76 | 13% YoY | 1 |
Latest Reports
MIXED
8-K
5/10
Spero Therapeutics reported Q1 2026 results with revenue plunging 95% to $0.3M as the Phase 3 trial ended, but net loss
May 13, 2026
NEUTRAL
DEFA14A
3/10
Spero Therapeutics filed additional proxy materials for its 2026 Annual Meeting, scheduled for June 23, 2026. Proposals
Apr 27, 2026
BULLISH
Press
8/10
Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $4.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $2.8M | ADD |
| TWO SIGMA INVESTMENTS, LP | $2.1M | DOUBLED |
| BlackRock, Inc. | $1.0M | — |
| CITADEL ADVISORS LLC | $880.9K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 4, 2026 | Rajavelu Esther | SELL | $63.4K |
| Feb 6, 2026 | Keutzer Timothy | SELL | $44.0K |
| Feb 6, 2026 | Rajavelu Esther | SELL | $87.6K |
| Feb 4, 2026 | Keutzer Timothy | SELL | $7.8K |
| Feb 3, 2026 | Keutzer Timothy | SELL | $51.8K |
Reddit Sentiment
56°
Neutral
Bearish
Neutral
Bullish
23 institutional holders with $14.1M total value (6,029,581 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,799,880 | $4.2M | 29.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,189,235 | $2.8M | 19.7% | ADD +74.6% |
| 3 | TWO SIGMA INVESTMENTS, LP | 885,631 | $2.1M | 14.7% | DOUBLED +654.2% |
| 4 | BlackRock, Inc. | 433,202 | $1.0M | 7.2% | — |
| 5 | CITADEL ADVISORS LLC | 376,458 | $880.9K | 6.2% | TRIM -73.9% |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 333,115 | $779.5K | 5.5% | — |
| 7 | VANGUARD FIDUCIARY TRUST CO | 264,115 | $618.0K | 4.4% | — |
| 8 | STATE STREET CORP | 214,751 | $502.5K | 3.6% | — |
| 9 | MARSHALL WACE, LLP | 157,072 | $367.5K | 2.6% | — |
| 10 | Point72 Asset Management, L.P. | 59,668 | $139.6K | 1.0% | ADD +36.9% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 48,500 | $113.5K | 0.8% | — |
| 12 | Invesco Ltd. | 45,374 | $106.2K | 0.8% | ADD +83.7% |
| 13 | OMERS ADMINISTRATION Corp | 39,400 | $92.2K | 0.7% | TRIM -70.0% |
| 14 | DIMENSIONAL FUND ADVISORS LP | 29,768 | $69.2K | 0.5% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 28,565 | $66.8K | 0.5% | — |
| 16 | CITADEL ADVISORS LLC | 26,700 | $62.5K | 0.4% | TRIM -73.9% |
| 17 | Vanguard Global Advisers, LLC | 25,446 | $59.5K | 0.4% | — |
| 18 | CITADEL ADVISORS LLC | 22,500 | $52.6K | 0.4% | TRIM -73.9% |
| 19 | CITIGROUP INC | 19,135 | $44.8K | 0.3% | — |
| 20 | Assenagon Asset Management S.A. | 18,636 | $43.6K | 0.3% | TRIM -49.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | ADD | 43,579 | 59,668 | +36.9% | $139.6K | 2026-Q1 |
| Invesco Ltd. | ADD | 24,705 | 45,374 | +83.7% | $106.2K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 131,127 | 39,400 | -70.0% | $92.2K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 313 | 4,552 | +1354.3% | $10.7K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 49,399 | 372,570 | +654.2% | $868.1K | 2025-Q4 |
| Assenagon Asset Management S.A. | TRIM | 36,993 | 18,636 | -49.6% | $43.4K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 43,378 | 313 | -99.3% | $729.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 832,165 | 1,452,765 | +74.6% | $2.7M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 9,221 | 43,378 | +370.4% | $81.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 8,194 | 27,101 | +230.7% | $51.0K | 2025-Q3 |
| Invesco Ltd. | ADD | 14,968 | 22,100 | +47.6% | $41.5K | 2025-Q3 |
| GROUP ONE TRADING LLC | DOUBLED | 8,239 | 16,879 | +104.9% | $31.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 5,633 | 733 | -87.0% | $1.4K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,826 | 8,194 | +190.0% | $23.8K | 2025-Q2 |
| UBS Group AG | DOUBLED | 141 | 2,826 | +1904.3% | $2.0K | 2025-Q1 |
| MACKENZIE FINANCIAL CORP | DOUBLED | 31,903 | 187,559 | +487.9% | $193.2K | 2024-Q4 |
| FMR LLC | ADD | 3,139 | 4,289 | +36.6% | $4.4K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 17,529 | 141 | -99.2% | $145.00 | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 312,034 | 81,425 | -73.9% | $109.1K | 2024-Q3 |
2 unique insiders with 11 transactions. Net insider value: -$336.7K ($0.00 bought, $336.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 4, 2026 | Rajavelu Esther | See Remarks | SELL | 25,240 | $2.51 | $63.4K |
| Feb 6, 2026 | Keutzer Timothy | Chief Operating Officer | SELL | 18,652 | $2.36 | $44.0K |
| Feb 6, 2026 | Rajavelu Esther | See Remarks | SELL | 37,101 | $2.36 | $87.6K |
| Feb 4, 2026 | Keutzer Timothy | Chief Operating Officer | SELL | 3,471 | $2.24 | $7.8K |
| Feb 3, 2026 | Keutzer Timothy | Chief Operating Officer | SELL | 24,224 | $2.14 | $51.8K |
| Feb 2, 2026 | Keutzer Timothy | Chief Operating Officer | AWARD | 68,000 | — | — |
| Feb 2, 2026 | Keutzer Timothy | Chief Operating Officer | SELL | 18,891 | $2.20 | $41.6K |
| Feb 2, 2026 | Keutzer Timothy | Chief Operating Officer | AWARD | 137,000 | — | — |
| Feb 2, 2026 | Rajavelu Esther | See Remarks | AWARD | 249,000 | — | — |
| Feb 2, 2026 | Rajavelu Esther | See Remarks | SELL | 18,442 | $2.20 | $40.6K |
| Feb 2, 2026 | Rajavelu Esther | See Remarks | AWARD | 498,000 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 4.0/10.
Historical analyst distribution (last covering-analyst action Jan 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2025. No current recommendation available.
$4.00 mean target (Jan 2025)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $2.85 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.67 | $0.67 | $0.67 | 346.7% | +0.0% | — | $0.0B | — | 1 |
| Next FY 2027-12-31 |
$0.76 | $0.76 | $0.76 | 13.4% | — | 1↑ 0↓ | $0.0B | — | 1 |
10 analyst firms have rated this stock: 2 upgrades, 7 downgrades, 8 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 30, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 20, 2024 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Dec 2, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 18, 2024 | TD Cowen | DOWNGRADE | Buy | Hold |
| Nov 15, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Nov 4, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 6, 2024 | TD Cowen | UPGRADE | Hold | Buy |
| Aug 6, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Aug 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 4, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Mar 18, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 1, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 20, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 10, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Sep 26, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Sep 23, 2022 | Evercore ISI Group | UPGRADE | In-Line | Outperform |
| Aug 15, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 23, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 20, 2022 | Berenberg | DOWNGRADE | Buy | Hold |
| May 17, 2022 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| May 4, 2022 | Cowen & Co. | DOWNGRADE | Outperform | Market Perform |
| May 4, 2022 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Apr 18, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 21, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Oct 1, 2021 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Jan 22, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Dec 16, 2020 | Berenberg | INITIATE | — | Buy |
| Nov 23, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Sep 29, 2020 | Evercore ISI Group | INITIATE | — | Outperform |
| May 11, 2020 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 17, 2020 | Stifel | MAINTAIN | — | Buy |
| Nov 5, 2019 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Sep 9, 2019 | Janney Montgomery Scott | INITIATE | — | Buy |
| Oct 16, 2018 | B of A Securities | DOWNGRADE | Neutral | Underperform |
| May 11, 2018 | HC Wainwright & Co. | INITIATE | — | Buy |
| Feb 9, 2018 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Nov 27, 2017 | B of A Securities | INITIATE | — | Neutral |
| Nov 27, 2017 | Cowen & Co. | INITIATE | — | Outperform |
| Nov 27, 2017 | Stifel | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
56°
Neutral
Bearish
Neutral
Bullish
5 mentions
1 bullish
0 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 17, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 17, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 18, 2026
fda_pdufa
PDUFA: SPRO — tebipenem HBr in complicated urinary tract infections (cUTI), including pyelonephritis — 2026-06-18
FDA target action date 2026-06-18 for SPRO (Spero Therapeutics, Inc.). Drug: tebipenem HBr. Indication: complicated urinary tract infections (cUTI), i
May 13, 2026
earnings_calendar
SPRO Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
SPRO Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
earnings
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
<p align="left">CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=C2o88yc237dX8DY3Giv-kM8DUX8oT
Mar 26, 2026
earnings
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
<p>CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ObpwaSMYUB4IceJFnmMIqSUE0eUwptKA2dhBS5bn
Mar 26, 2026
earnings_calendar
SPRO Q4 2025 Earnings After Market Close — 2026-03-26
Mar 18, 2026
earnings
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
<p align="left">CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=inPaeH-wpwa0GlXmxg4HT--bpG_